Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: Implications for HIT pathogenesis

Blood

Volumn 125, Issue 1, 2015, Pages 155-161

  Padmanabhan, Anand ^a,b   Jones, Curtis G ^a   Bougie, Daniel W ^a   Curtis, Brian R ^a   McFarland, Janice G ^a,b   Wang, Demin ^a,b   Aster, Richard H ^a,b  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN 4 SULFATE; CHONDROITIN ABC LYASE; EPITOPE; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN G; PADGEM PROTEIN; THROMBOCYTE FACTOR 4; ANTIBODY; CHONDROITIN SULFATE; HEPARITINSULFATE LYASE; POLYSACCHARIDE LYASE; PROTEIN BINDING; SEROTONIN;

ANTIGEN BINDING; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS; HUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOSIS; CHEMICALLY INDUCED; CHEMISTRY; IMMUNOLOGY; THROMBOCYTE; THROMBOCYTOPENIA;

ANTIBODIES; BLOOD PLATELETS; CHONDROITIN SULFATES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GLYCOSAMINOGLYCANS; HEPARIN; HUMANS; IMMUNOGLOBULIN G; P-SELECTIN; PLATELET ACTIVATION; PLATELET FACTOR 4; POLYSACCHARIDE-LYASES; PROTEIN BINDING; SEROTONIN; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84920555104     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-580894     Document Type: Article

References (41)

1. Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest. 2009; 135(6): 1651-1664.
2. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. Annu Rev Med. 2010; 61: 77-90.
3. Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost. 2012; 38(5): 483-496.
4. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994; 93(1): 81-88.
5. Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994; 71(2): 247-251.
6. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992; 68(1): 95-96.
7. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996; 101(5): 502-507.
8. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005; 94(1): 132-135.
9. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000; 96(1): 182-187.
10. Hirsh J, Anand SS, Halperin JL, Fuster V; American Heart Association. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001; 103(24): 2994-3018.
11. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999; 106(6): 629-635.
12. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000; 96(3): 846-851.
13. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001; 135(7): 502-506.
14. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002; 136(3): 210-215.
15. Prechel MM, McDonald MK, Jeske WP, Messmore HL, Walenga JM. Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost. 2005; 3(10): 2168-2175.
16. Aster RH Heparin-independent activation of platelets by HIT antibodies: a clue to the etiology of delayed thrombocytopenia/thrombosis in patients given heparin? J Thromb Haemost. 2005; 3(10): 2166-2167.
17. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006; 107(6): 2346-2353.
18. McFarland J, Lochowicz A, Aster R, Chappell B, Curtis B. Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia. Am J Hematol. 2012; 87(8): 776-781.
19. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986; 67(1): 27-30.
20. Stoddard E, Cannon G, Ni H, et al. gp340 expressed on human genital epithelia binds HIV-1 envelope protein and facilitates viral transmission. J Immunol. 2007; 179(5): 3126-3132.
21. Nader HB Characterization of a heparan sulfate and a peculiar chondroitin 4-sulfate proteoglycan from platelets. Inhibition of the aggregation process by platelet chondroitin sulfate proteoglycan. J Biol Chem. 1991; 266(16): 10518-10523.
22. Rauova L, Hirsch JD, Greene TK, et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood. 2010; 116(23): 5021-5031.
23. Horne MK III, Alkins BR. Platelet binding of IgG from patients with heparin-induced thrombocytopenia. J Lab Clin Med. 1996; 127(5): 435-442.
24. Horne MK III, Hutchison KJ. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol. 1998; 58(1): 24-30.
25. Arepally GM, Kamei S, Park KS, et al. Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood. 2000; 95(5): 1533-1540.
26. Raschke RA, Curry SC, Warkentin TE, Gerkin RD. Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood ratios, and Bayes theorem. Chest. 2013; 144(4): 1269-1275.
27. Cuker A, Rux AH, Hinds JL, et al. Novel diagnostic assays for heparin-induced thrombocytopenia. Blood. 2013; 121(18): 3727-3732.
28. Okayama M, Oguri K, Fujiwara Y, et al. Purification and characterization of human platelet proteoglycan. Biochem J. 1986; 233(1): 73-81.
29. Barber AJ, Käser-Glanzmann R, Jakábová M, Lüscher EF. Characterization of a chondroitin 4-sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Biochim Biophys Acta. 1972; 286(2): 312-329.
30. Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood. 1998; 92(9): 3250-3259.
31. Li ZQ, Liu W, Park KS, et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HITlike monoclonal antibody. Blood. 2002; 99(4): 1230-1236.
32. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood. 1998; 91(3): 916-922.
33. Brandt S, Krauel K, Gottschalk KE, et al. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. Thromb Haemost. 2014; 112(1): 53-64.
34. Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001; 138(1): 22-31.
35. Busch C, Dawes J, Pepper DS, Wasteson A. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res. 1980; 19(1-2): 129-137.
36. Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, Poncz M. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood. 2007; 110(4): 1153-1160.
37. Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood. 2014; 123(23): 3651-3654.
38. Warkentin TE, Greinacher A, Koster A, Lincoff AM; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl): 340S-380S.
39. Warkentin TE How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program. 2011; 2011: 143-149.
40. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol. 2007; 82(12): 1037-1043.
41. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995; 332(20): 1330-1335.